Showing 3321-3330 of 18626 results for "".
SHTG: Defining the Unmet Clinical Need
https://reachmd.com/programs/cme/shtg-defining-the-unmet-clinical-need/33224/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
https://reachmd.com/programs/cme/setting-the-bar-guideline-recommended-treatment-in-hypertriglyceridemia/33221/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
https://reachmd.com/programs/cme/from-data-to-debate-global-perspectives-on-hrher2-mbc-care/37268/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
https://reachmd.com/programs/cme/unmet-needs-in-endocrine-therapy-rethinking-the-hrher2-mbc-treatment-roadmap/39797/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
https://pace-cme.org/topics/heart-failure/novel-therapies-in-managing-patients-with-cardiovascular-kidney-metabolic-syndrome-and-heart-failure/35688/CKM syndrome and HFpEF overlap; discover how SGLT2i, GLP-1 RAs & nsMRAs offer a powerful approach to improve heart and kidney health.Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
https://reachmd.com/clinical-practice/cardiology/kidney-risk-stratification-in-finerenone-treatment-finearts-hf-trial/32987/Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves outcomes in HFmrEF/HFpEF across all KDIGO kidney risk categories.Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
https://reachmd.com/clinical-practice/cardiology/effect-of-finerenone-on-nt-probnp-in-hfmrefhfpef-finearts-hf-trial/32986/Dr. Cunningham discusses new data from ACC 2025 showing that finerenone lowers NT-proBNP and improves outcomes in patients with HFmrEF/HFpEF.Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
https://reachmd.com/programs/cme/beyond-fulvestrant-oral-serds-redefining-er-targeting/39800/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.SHTG: Decoding the Latest Clinical Trial Outcomes
https://reachmd.com/programs/cme/shtg-decoding-the-latest-clinical-trial-outcomes/33225/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Latest Clinical Trial Outcomes and Breakthroughs for FCS
https://reachmd.com/programs/cme/latest-clinical-trial-outcomes-and-breakthroughs-for-fcs/33223/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.